Chemotherapy and the war on cancer (original) (raw)

• Papac, R. J. Origins of cancer therapy. Yale J. Biol. Med. 74, 391–398 (2001).
  CAS PubMed PubMed Central Google Scholar
• Gilman, A. The initial clinical trial of nitrogen mustard. Am. J. Surg. 105, 574–578 (1963).
  Article CAS PubMed Google Scholar
• Gilman, A. The biological actions and therapeutic applications of the B-chloroethyl amines and sulfides. Science 103, 409–436 (1946).
  Article CAS PubMed Google Scholar
• Wills, L., Clutterbuch, P. & Evans, B. D. F. A new factor in the production and cure of macrocytic anaemias and its relation to other haemopoietic principles curative in pernicious anaemia. Biochem. J. 31, 2136–2147 (1937).
  Article CAS PubMed PubMed Central Google Scholar
• Farber, S., Diamond, L. K., Mercer, R. D., Sylvester, R. F. & Wolff, J. A. Temporary remissions in acute leukemia in children produced by folic antagonist, 4-aminopteroylglutamic acid (aminopterin). N. Engl. J. Med. 238, 787–793 (1948).
  Article CAS PubMed Google Scholar
• Bonadonna, G. et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N. Engl. J. Med. 294, 405–410 (1976).
  Article CAS PubMed Google Scholar
• Li, M. C., Hertz, R. & Bergenstal, D. M. Therapy of choriocarcinoma and related trophoblastic tumors with folic acid and purine antagonists. N. Engl. J. Med. 259, 66–74 (1958).
  Article CAS PubMed Google Scholar
• Jaffe, N., Frei, E. 3rd, Traggis, D. & Bishop, Y. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N. Engl. J. Med. 291, 994–997 (1974).
  Article CAS PubMed Google Scholar
• Jaffe, N. et al. High-dose methotrexate in osteogenic sarcoma. Natl Cancer Inst. Monogr. 56, 201–206 (1981).
  Google Scholar
• Osborn, M. J., Freeman, M. & Huennekens, F. M. Inhibition of dihydrofolic reductase by aminopterin and amethopterin. Proc. Soc. Exp. Biol. Med. 97, 429–431 (1958).
  Article CAS PubMed Google Scholar
• Osborn, M. J. & Huennekens, F. M. Enzymatic reduction of dihydrofolic acid. J. Biol. Chem. 233, 969–974 (1958).
  Article CAS PubMed Google Scholar
• Jolivet, J., Cowan, K. H., Curt, G. A., Clendeninn, N. J. & Chabner, B. A. The pharmacology and clinical use of methotrexate. N. Engl. J. Med. 309, 1094–104 (1983).
  Article CAS PubMed Google Scholar
• Messmann, R. A. & Allegra, C. J. in Cancer Chemotherapy and Biotherapy (eds Chabner, B. A. & Longo, D.) 139–184 (Lippincott Williams & Wilkins, Philadelphia, 2001).
  Google Scholar
• Curt, G. A., Clendeninn, N. J. & Chabner, B. A. Drug resistance in cancer. Cancer Treat. Rep. 68, 87–99 (1984).
  CAS PubMed Google Scholar
• Stoller, R. G., Hande, K. R., Jacobs, S. A., Rosenberg, S. A. & Chabner, B. A. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N. Engl. J. Med. 297, 630–634 (1977).
  Article CAS PubMed Google Scholar
• Skipper, H. E., Thomson, J. R., Elion, G. B. & Hitchings, G. H. Observations on the anticancer activity of 6-mercaptopurine. Cancer Res. 14, 294–298 (1954).
  CAS PubMed Google Scholar
• Hitchings, G. H. & Elion, G. B. The chemistry and biochemistry of purine analogs. Ann. NY Acad. Sci. 60, 195–199 (1954).
  Article CAS PubMed Google Scholar
• Johnson, I. S., Armstrong, J. G., Gorman, M. & Burnett, J. P. Jr. The Vinca alkaloids: a new class of oncolytic agents. Cancer Res. 23, 1390–1427 (1963).
  CAS PubMed Google Scholar
• Bensch, K. G. & Malawista, S. E. Microtubule crystals: a new biophysical phenomenon induced by Vinca alkaloids. Nature 218, 1176–1177 (1968).
  Article CAS PubMed Google Scholar
• Frei, E. 3rd et al. The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood 26, 642–656 (1965).
  Article PubMed Google Scholar
• Frei, E. 3rd. The National Cancer Chemotherapy Program. Science 217, 600–606 (1982).
  Article PubMed Google Scholar
• Driscoll, J. S. The preclinical new drug research program of the National Cancer Institute. Cancer Treat. Rep. 68, 63–76 (1984).
  CAS PubMed Google Scholar
• Grever, M. R., Schepartz, S. A. & Chabner, B. A. The National Cancer Institute: cancer drug discovery and development program. Semin. Oncol. 19, 622–638 (1992).
  CAS PubMed Google Scholar
• Skipper, H. E., Schabel, F. M. Jr. & Wilcox, W. S. Experimental evaluation of potential anticancer agents. Xiii. On the criteria and kinetics associated with 'curability' of experimental leukemia. Cancer Chemother. Rep. 35, 1–111 (1964).
  CAS PubMed Google Scholar
• Skipper, H. E. & Griswold, D. P. Frank M. Schabel 1918–1983. Cancer Res. 44, 871–872 (1984).
  CAS PubMed Google Scholar
• Moxley, J. H. 3rd, De Vita, V. T., Brace, K. & Frei, E. 3rd. Intensive combination chemotherapy and X-irradiation in Hodgkin's disease. Cancer Res. 27, 1258–1263 (1967).
  PubMed Google Scholar
• Devita, V. T. Jr., Serpick, A. A. & Carbone, P. P. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann. Intern. Med. 73, 881–895 (1970).
  Article PubMed Google Scholar
• Levitt, M. et al. Combination sequential chemotherapy in advanced reticulum cell sarcoma. Cancer 29, 630–636 (1972).
  Article CAS PubMed Google Scholar
• Berd, D., Cornog, J., DeConti, R. C., Levitt, M. & Bertino, J. R. Long-term remission in diffuse histiocytic lymphoma treated with combination sequential chemotherapy. Cancer 35, 1050–1054 (1975).
  Article CAS PubMed Google Scholar
• Moertel, C. G. et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med. 322, 352–358 (1990).
  Article CAS PubMed Google Scholar
• McGuire, W. P. et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Intern. Med. 111, 273–279 (1989).
  Article CAS PubMed Google Scholar
• Goodman, J. & Walsh, V. The Story of Taxol: Nature and Politics in the Pursuit of an Anti-cancer Drug (Cambridge Univ., Cambridge, 2001).
  Google Scholar
• Saltz, L. B. et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. 343, 905–914 (2000).
  Article CAS PubMed Google Scholar
• Noda, K. et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 346, 85–91 (2002).
  Article CAS PubMed Google Scholar
• Bodurka, D. C. et al. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J. Clin. Oncol. 21, 291–297 (2003).
  Article PubMed CAS Google Scholar
• Von Hoff, D. D. There are no bad anticancer agents, only bad clinical trial designs — twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin. Cancer Res. 4, 1079–1086 (1998).
  CAS PubMed Google Scholar
• Johnson, J. I. et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 84, 1424–1431 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Rosenberg, B., Vancamp, L. & Krigas, T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205, 698–699 (1965).
  Article CAS PubMed Google Scholar
• Bosl, G. J. et al. VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors. J. Clin. Oncol. 4, 1493–1499 (1986).
  Article CAS PubMed Google Scholar
• Evans, B. D., Raju, K. S., Calvert, A. H., Harland, S. J. & Wiltshaw, E. Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma. Cancer Treat. Rep. 67, 997–1000 (1983).
  CAS PubMed Google Scholar
• Montgomery, J. A. Chemistry and structure-activity studies of the nitrosoureas. Cancer Treat. Rep. 60, 651–664 (1976).
  CAS PubMed Google Scholar
• Walker, M. D. & Hurwitz, B. S. BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea; NSC-409962) in the treatment of malignant brain tumor — a preliminary report. Cancer Chemother. Rep. 54, 263–271 (1970).
  CAS PubMed Google Scholar
• Wilson, C. B., Boldrey, E. B. & Enot, K. J. 1,3-bis (2-chloroethyl)-1-nitrosourea (NSC-409962) in the treatment of brain tumors. Cancer Chemother. Rep. 54, 273–281 (1970).
  CAS PubMed Google Scholar
• Rai, K. R. et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med. 343, 1750–1757 (2000).
  Article CAS PubMed Google Scholar
• Minocha, A. & Long, B. H. Inhibition of the DNA catenation activity of type II topoisomerase by VP16-213 and VM26. Biochem. Biophys. Res. Commun. 122, 165–170 (1984).
  Article CAS PubMed Google Scholar
• Freireich, E. J., Schmidt, P. J., Schneiderman, M. A. & Frei, E. 3rd. A comparative study of the effect of transfusion of fresh and preserved whole blood on bleeding in patients with acute leukemia. N. Engl. J. Med. 260, 6–11 (1959).
  Article CAS PubMed Google Scholar
• Gaydos, L. A., Freireich, E. J. & Mantel, N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N. Engl. J. Med. 266, 905–909 (1962).
  Article CAS PubMed Google Scholar
• Pizzo, P. A. Granulocytopenia and cancer therapy. Past problems, current solutions, future challenges. Cancer 54, 2649–2661 (1984).
  Article CAS PubMed Google Scholar
• Lieschke, G. J. & Burgess, A. W. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1). N. Engl. J. Med. 327, 28–35 (1992).
  Article CAS PubMed Google Scholar
• Lieschke, G. J. & Burgess, A. W. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2). N. Engl. J. Med. 327, 99–106 (1992).
  Article CAS PubMed Google Scholar
• Curtis, R. E. et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N. Engl. J. Med. 326, 1745–1751 (1992).
  Article CAS PubMed Google Scholar
• Burstein, H. J. & Winer, E. P. Primary care for survivors of breast cancer. N. Engl. J. Med. 343, 1086–1094 (2000).
  Article CAS PubMed Google Scholar
• Johnson, J., Monks, A., Hollingshead, M. & Sausville, E. in Cancer Chemotherapy and Biotherapy (eds Chabner, B. A. & Longo, D.) 17–36 (Lippincott Williams & Wilkins, Philadelphia, 2001).
• Whitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E. & Neckers, L. M. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl Acad. Sci. USA 91, 8324–8328 (1994).
  Article CAS PubMed PubMed Central Google Scholar
• Worland, P. J. et al. Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity. Biochem. Pharmacol. 46, 1831–1840 (1993).
  Article CAS PubMed Google Scholar
• Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55–63 (1983).
  Article CAS PubMed Google Scholar
• Paull, K. D. et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl Cancer Inst. 81, 1088–1092 (1989).
  Article CAS PubMed Google Scholar
• Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
  Article CAS PubMed Google Scholar
• Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR–ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031–1037 (2001).
  Article CAS PubMed Google Scholar
• Kantarjian, H. et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346, 645–652 (2002).
  Article CAS PubMed Google Scholar
• Hughes, T. P. et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349, 1423–1432 (2003).
  Article CAS PubMed Google Scholar
• Shah, N. P. et al. Multiple BCR–ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117–125 (2002).
  Article CAS PubMed Google Scholar
• Roche-Lestienne, C. et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100, 1014–1018 (2002).
  Article CAS PubMed Google Scholar
• Branford, S. et al. Detection of BCR–ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102, 276–283 (2003).
  Article CAS PubMed Google Scholar
• Kris, M. G. et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290, 2149–2158 (2003).
  Article CAS PubMed Google Scholar
• Giaccone, G. et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial — INTACT 1. J. Clin. Oncol. 22, 777–784 (2004).
  Article CAS PubMed Google Scholar
• Herbst, R. S. et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial — INTACT 2. J. Clin. Oncol. 22, 785–794 (2004).
  Article CAS PubMed Google Scholar
• Cunningham, D. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337–345 (2004).
  Article CAS PubMed Google Scholar
• Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004).
  Article CAS PubMed Google Scholar
• Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004).
  Article CAS PubMed Google Scholar
• Roberts, T. G. Jr. & Chabner, B. A. Beyond fast track for drug approvals. N. Engl. J. Med. 351, 501–505 (2004).
  Article CAS PubMed Google Scholar
• Adjei, A. A. et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 21, 1760–1766 (2003).
  Article CAS PubMed Google Scholar
• Sharma, S. et al. A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Ann. Oncol. 13, 1067–1071 (2002).
  Article CAS PubMed Google Scholar
• Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182–1186 (1971).
  Article CAS PubMed Google Scholar
• Gnarra, J. R. et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nature Genet. 7, 85–90 (1994).
  Article CAS PubMed Google Scholar
• Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335–2342 (2004).
  Article CAS PubMed Google Scholar
• Roninson, I. B. et al. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc. Natl Acad. Sci. USA 83, 4538–4542 (1986).
  Article CAS PubMed PubMed Central Google Scholar
• Coiffier, B. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 235–242 (2002).
  Article CAS PubMed Google Scholar
• Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001).
  Article CAS PubMed Google Scholar
• Reed, J. C. Dysregulation of apoptosis in cancer. J. Clin. Oncol. 17, 2941–2953 (1999).
  Article CAS PubMed Google Scholar
• Zubrod, C. G. The national program for cancer chemotherapy. JAMA 222, 1161–1162 (1972).
  Article CAS PubMed Google Scholar
• Takimoto, C. H. Anticancer drug development at the US National Cancer Institute. Cancer Chemother. Pharmacol. 52 (Suppl. 1), 29–33 (2003).
  Article CAS Google Scholar
• Kelland, L. R. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur. J. Cancer 40, 827–836 (2004).
  Article CAS PubMed Google Scholar
• Boyd, M. R. in Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval (ed. Teicher, B.) 23 (Humana, Totowa, 1997).
  Book Google Scholar
• S. G. Cowen & Company. Pharmaceutical Therapeutic Categories Outlook: Comprehensive Study 375 (S.G. Cowen & Company, New York, 2004).
• Schrag, D. The price tag on progress — chemotherapy for colorectal cancer. N. Engl. J. Med. 351, 317–319 (2004).
  Article CAS PubMed Google Scholar
• Ernst & Young LLP, Annual Biotechnology Industry Report, 2001. In Parexel's Pharmaceutical R&D Statistical Sourcebook (Parexel, Walthan, 2002/2003).
• Pharmaceuticals Research and Manufacturers of America. New medicines in development for cancer: 395 new medicines in development offer hope in the war on cancer 1–56 (PhRMA, Washington, 2003).
• IMS LifeCycle, R&D focus. In Parexel's Pharmaceutical R&D Statisitcal Sourcebook (Parexel, Walthan, 2003/2004).
• Chabner, B. The traveling oncologist and the wages of sin. Oncologist 6, 1–2 (2001).
  Article Google Scholar
• Gorlick, R. et al. Intrinsic and acquired resistance to methotrexate in acute leukemia. New Engl. J. Med. 335, 1041–1048 (1996).
  Article CAS PubMed Google Scholar